Fig. 2. (A) Cu-Phen and ternary copper(ii) phenanthrene complexes Cu-DPQ-Phen, Cu-DPPZ-Phen and Cu-DPPN-Phen; (B) di-nuclear copper(ii) terephthalate (Cu-Terph) and octanedioate (Cu-Oda) complexes; (C) square planar copper(ii) complex Cu-Ph-Phen incorporating o-phthalate and 1,10-phenanthroline; (D) polynuclear platinum complexes (PPCs) [{transPtCl(NH3)2}2-μ-{trans-Pt(NH3)2(NH2(CH2)6NH2)2}]4+ (Triplatin, BBR3464), [{Pt(NH3)3}2-μ-{trans-Pt(NH3)2(NH2(CH2)6NH2)2}]6+ (AH44), and [{transPt(NH3)2(NH2(CH2)6NH3)}2-μ-({trans-Pt(NH3)2(NH2(CH2)6NH2)2})]8+ (TriplatinNC); and (E) Minor groove binding agents 4′,6-diamidino-2-phenylindole (DAPI), netropsin (Net), Hoechst 33258; (F) major groove binding methyl green (MG); and (G). planar heterocyclic intercalators propidium iodide (PI), ethidium bromide (EtBr) and doxorubicin (Dox).
